![Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial]()
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trialTabernero, Josep; Lenz, Heinz-Josef; Siena, Salvatore; Sobrero, Alberto; Falcone, Alfredo; Ychou, Marc; Humblet, Yves; Bouché, Olivier; Mineur, Laurent; Barone, Carlo; Adenis, Antoine; Yoshino, Takayuki; Goldberg, Richard M; Sargent, Daniel J; Wagner, Andrea; Laurent, Dirk; Teufel, Michael; Jeffers, Michael; Grothey, Axel; Van Cutsem, Eric · The Lancet Oncology · 2015